FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular, an antibody binding human IL-4R, an antigen-binding fragment thereof, and a medical application thereof. Proposed are a chimeric antibody and a humanised antibody, including a CDR region from an antibody binding human IL-4R and an antigen-binding fragment thereof; a pharmaceutical composition including an antibody binding human IL-4R and an antigen-binding fragment thereof, and an application thereof as a medicinal product treating an allergic disease. Also proposed is an application of the humanised IL-4R-binding antibody in the production of a medicinal product used to treat IL-4R-mediated conditions or diseases.
EFFECT: invention allows for effective treatment of IL-4R mediated diseases.
17 cl, 1 dwg, 12 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
